Learn how and why Atom Bioscience is developing a new treatment for gout — and the impact it may have on millions of lives.

Atom Bioscience (Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.) is a clinical stage biotechnology company founded in 2012. Atom is developing best-in-class orally delivered small molecule drugs for treatment of inflammatory and metabolic diseases, such as chronic gout and non-alcoholic steatohepatitis (NASH) for which there are no effective treatments.

Atom’s lead therapy, ABP-671, for chronic gout, is more potent and significantly less toxic than existing drugs, and is poised to enter global Phase 3 trials in 2023. Another compound, ABP-6016, has demonstrated safety and efficacy in preclinical trials for NASH, which is projected to become the most common cause of liver disease.

Latest News from Atom Bioscience

Endpoints: Atom Bioscience raises $83M in Series D for URAT1 inhibitor in chronic gout treatment
Atom Bioscience Raises $83M in a D-Round Financing to Support Global Pivotal Clinical Trials of ABP-671, a New Treatment for Chronic Gout
BioSpace: Atom Bioscience Doses First Patient in Phase 2b/3 Clinical Trial of a New Treatment for Chronic Gout
Atom Bioscience Doses First Patient in Phase 2b/3 Clinical Trial of a New Treatment for Chronic Gout